Evaluation of Daunorubicin, Cytarabine, and Mitoxantrone Efficacy in Pediatric Acute Myeloid Leukemia Treatment: A NOPHO-DBH AML 2012 Protocol Study

The primary objective of the NOPHO-DBH AML 2012 Protocol is to enhance the prognosis for children and adolescents with **acute myeloid leukemia** (AML) by implementing improved risk stratification through minimal residual disease (MRD) quantification and more intensive induction therapy compared to previous NOPHO protocols. This is clinically relevant as it aims to optimize treatment efficacy and improve survival outcomes in this vulnerable population. Specific research aims include evaluating the efficacy of DaunoXome® versus Mitoxantrone in the first treatment course, assessing the efficacy of FLADx compared to ADxE in the second induction course, and investigating the correlation and prognostic impact of MRD measurement by PCR and flow cytometry after the first and second courses.

Secondary objectives include: - Improving both event-free survival (EFS) and overall survival (OS) compared to NOPHO-AML 93 and 2004 protocols. - Enhancing EFS and OS for patients with intermediate response (5-14.9% blasts) after the first course and those with t(8;21) translocation. - Achieving an improved anti-leukemic effect without increasing early toxic deaths or deaths in complete remission (CR). - Comparing outcomes in patient subgroups defined by characteristics such as age, FAB type, and cytogenetics, including t(8;21), inv(16), and MLL rearrangements. - Comparing the incidence of severe infections and severe organ toxicity between treatment arms and previous protocols.

The clinical trial involves a total of **200 participants** diagnosed with **Acute Myeloid Leukemia** (AML), specifically targeting a pediatric population aged 0 to 18 years. The study includes both male and female subjects, ensuring a comprehensive representation of the pediatric demographic affected by this condition. Participants were selected based on specific inclusion criteria, including a confirmed diagnosis of AML as per the protocol's diagnostic criteria, being under 19 years of age at the time of diagnosis, and having provided written informed consent. The trial population is considered vulnerable due to the age range and the nature of the disease. Lifestyle considerations such as diet, physical activity, or habits are not specified in the available data. The study aims to improve prognosis through better risk stratification and more intensive induction therapy, with a focus on evaluating the efficacy of different treatment regimens and the prognostic impact of minimal residual disease (MRD) measurement.

The clinical trial is designed to evaluate the efficacy of various chemotherapeutic agents in the treatment of **acute myeloid leukemia** (AML) in pediatric patients aged 0-18 years. This is a Phase III, randomized, double-blind, controlled trial with the primary objective of improving prognosis through better risk stratification and more intensive induction therapy. The trial involves the administration of **etoposide**, **cytarabine**, **daunorubicin**, **daunorubicin hydrochloride**, **mitoxantrone**, and **fludarabine phosphate**, all delivered intravenously. The maximum treatment period for each drug is six months, with specific dosing regimens tailored to each active substance.

The trial is expected to run from March 2013 to September 2029, with participant involvement lasting up to six months, depending on individual response and tolerance to the treatment. The study includes several key visits: an initial screening visit to confirm eligibility based on diagnostic criteria, age, and informed consent; multiple follow-up visits to monitor treatment response and adverse events; and an end-of-study visit to assess overall outcomes. The primary endpoints include the fraction of patients achieving minimal residual disease (MRD) levels below 0.1% after the first and second induction courses, as quantified by flow cytometry. Secondary endpoints focus on event-free survival, overall survival at five years, and cardiac function assessments.

Participants may be withdrawn from the study early if they experience severe adverse events, fail to comply with the study protocol, or if the investigator deems it in the participant's best interest. The trial aims to provide valuable insights into the comparative efficacy of the chemotherapeutic agents and the prognostic impact of MRD measurements, ultimately contributing to improved treatment strategies for pediatric AML.

The clinical trial involves the administration of several **experimental medications** for the treatment of pediatric acute myeloid leukemia (AML). **Etoposide** is utilized in the form of a powder for solution for injection. It is administered intravenously with a maximum daily dose of 150 mg/m² and a total maximum dose of 1700 mg/m² over a treatment period of up to 6 cycles. The active substance is of chemical origin.

**Cytarabine** is provided as a concentrate for solution for infusion. This medication is also administered intravenously, with a maximum daily dose of 6000 mg/m² and a total maximum dose of 45400 mg/m², over a maximum treatment period of 6 cycles. The active substance is chemically derived.

**Daunorubicin** is administered as an emulsion for infusion. The intravenous route is used, with a maximum daily dose of 60 mg/m² and a total maximum dose of 360 mg/m², over a treatment period of up to 6 cycles. The active substance is of chemical origin.

**Daunorubicin Hydrochloride** is provided in the form of a powder for infusion. It is administered intravenously, with a maximum daily dose of 60 mg/m² and a total maximum dose of 360 mg/m², over a treatment period of up to 6 cycles. The active substance is chemically derived.

**Mitoxantrone** is available as a concentrate for solution for infusion. It is administered intravenously, with a maximum daily dose of 10 mg/m² and a total maximum dose of 55 mg/m², over a treatment period of up to 6 cycles. The active substance is of chemical origin.

**Fludarabine Phosphate** is provided as a concentrate for solution for infusion. This medication is administered intravenously, with a maximum daily dose of 30 mg/m² and a total maximum dose of 300 mg/m², over a treatment period of up to 6 cycles. The active substance is chemically derived.

All medications are administered intravenously, and participant compliance is monitored throughout the study. The trial does not include any non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. The study aims to evaluate the efficacy of these medications in improving the prognosis for children and adolescents with AML.

Efficacy in the clinical trial for the treatment of children and adolescents with **acute myeloid leukemia (AML)** will be assessed using several primary and secondary endpoints. The primary endpoints focus on the fraction of patients achieving a minimal residual disease (MRD) level below 0.1%, as quantified by flow cytometry, after the first and second induction courses. Additionally, for patients with fusion genes, MRD levels will be measured after both courses. These assessments aim to evaluate the efficacy of DaunoXome® compared to Mitoxantrone in the first course and FLADx compared to ADxE in the second induction course.

Secondary endpoints include event-free survival and overall survival at five years, the median MRD after each induction course, the rate of complete remission (CR) after one and two induction courses, cardiac function after one and five years, and the frequency of severe adverse events, early deaths, and deaths in CR. These endpoints will provide a comprehensive evaluation of the treatment's efficacy and safety profile. The trial is designed to improve prognosis through better risk stratification based on MRD quantification and more intensive induction therapy.